Navigation Links
Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
Date:9/5/2007

U.S. Biogeneric Agents to Reach $2 Billion in Sales by 2016, According to a

New Report from Decision Resources

WALTHAM, Mass., Sept. 5 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen, the leading manufacturer of biologic agents with biologic sales of more than $14 billion in 2006, and Genentech, the second leading biologics manufacturer with biologic sales of more than $9 billion in 2006, are bracing themselves for heavy pressure from biogeneric manufacturers. According to the new special report entitled Biogenerics 2007- 2016: Physician and Payer Acceptance Fuels Brand Erosion, Amgen products such as Enbrel, Epogen and Neupogen will be eroded by biogeneric sales in both the United States and Europe. In fact, on August 31, 2007, European regulators approved Sandoz's biogeneric epoetin alfa for patients with renal anemia and those receiving chemotherapy. Genentech products such as Rituxan/MabThera and Herceptin represent windfall opportunities for biogeneric hopefuls.

The report also reveals that, with the launch of biogeneric TNF-alpha inhibitors in 2012, the U.S. biogeneric market will expand substantially through 2016 and reach a total of more than $2 billion in annual sales.

"This growth in the U.S. biogeneric market will be driven by biogeneric TNF-alpha inhibitors for rheumatoid arthritis, which we project will generate $700 million in sales by 2016, and will be supported by biogeneric versions of interferon-betas for multiple sclerosis, Herceptin for breast cancer, and ESPs for chemotherapy-induced anemia, each of which will post more than $250 million in 2016 U.S. sales," said Andrew Merseth, analyst at Decision Resources.

About Biogenerics 2007-2016: Physician and Payer Acceptance Fuels Brand Erosion

Biogenerics 2007-2016: Physician and Payer Acceptance Fuels Brand Erosion covers 13 key biologic
'/>"/>

SOURCE Decision Resources, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Genentechs Winning Streak
2. TeraMedica embraces open source project
3. Center for Technology Transfer embraces "Cleantech"
4. Wisconsin Film Festival embraces new online ticket ordering system
5. Wisconsin Historical Society Embraces New Web Site Technology
6. Chippewa Valley Embraces Nanotechnology
7. Wisconsin early-stage companies must position themselves to get capital
8. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
9. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
10. Cellular Dynamics hits market with UW research heavyweights
11. Governors Growth Council hopes to go light on paperwork and heavy on ideas

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...c. 2 /PRNewswire-Asia-FirstCall/ -- Emerald Dairy,...etin Board: EMDY), a leading,producer and distribu...and,soybean products in China, today announced tha... of US Food & Drink Executive, a quarterly mag... in the food and beverage industry. , The...
(Date:12/2/2009)... According to the National Institu...s diagnosed with diabetes already have some stage ...mage to the retina caused by leaky blood vessels, ...tes and is one of the most feared diabetic complic... who,ve had diabetes for 10 years or more will exp...
(Date:12/1/2009)... Reportlinker.com announces that a...talogue: ,, Emerging Clinical Trial Locations ... healthcare and regulatory environment ,, htt...l-Trial-Locations---Eastern-Europe-Market-dynamics...nment.html ,, Over the last decade pharmaceuti...
(Date:12/1/2009)... 1 Expanding its European reach fo...arasota has appointed Lake Chemicals and Minerals ...d near Birmingham, England. ,, Osprey breeds t...ricultural, waste water, and environmental markets...rain fields, and clean up industrial and marine sp...
Breaking Biology Technology:Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8
...ty, LLC issues a review of,VioQuest Pharmaceutical...ing Value; Turnaround Leverages Product Opportunit...", This review is available at website: http://w...is a New Jersey-based biotechnology company,dedica...ful development of,novel drug therapies targeting ...
... PAREXEL,International Corporation (Nasdaq: PRXL ...anization, reveal that U.S. marketing,applications...nt in 2007.,While NME approvals reached a many-yea...stance (NAS) launches declined 19 percent to 25, d...ed to 28 in 2007, up from 21 filed,in 2006, accord...
...for-10 split ratio, SEATTLE, Aug. 25 Cell Therap...d that its Board of Directors has,authorized a 1-f...se split,will become effective as of August 31, 20...Lieu of Annual Meeting of,Shareholders held on Jun...thorize the Board, in its discretion, to effect a ...
Other Biology Technology:VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC 2PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back 2PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back 3PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back 4Cell Therapeutics, Inc. Announces Reverse Stock Split 2
(Date:12/2/2009)... The Manpei Suzuki Diabetes Foundation is pleased ...rize: Donald F. Steiner, MD, A. N. Pritzker Distin... Medicine and Biochemistry and Molecular Biology, ... inaugurated in 2008 to commemorate the 15th anniv...onoring those who have enlightened researchers in ...
(Date:12/2/2009)..., Before one of your muscles can twitch, before t...erve, a tiny floodgate of sortscalled an ion chann...rgans to let in the chemical signals that spur the...titute of Standards and Technology (NIST) has allo...surface membrane for the first time, potentially o...
(Date:12/2/2009)..., (Dec. 2, 2009) HOBOKEN, NJ According to the N...ent of Americans diagnosed with diabetes already h...retinopathy, damage to the retina caused by leaky ...ople with diabetes and is one of the most feared d...of all patients who,ve had diabetes for 10 years o...
Breaking Biology News(10 mins):Nervy research: Researchers take initial look at ion channels in a model system 2Study shows pine bark improves circulation, swelling and visual acuity in early diabetic retinopathy 2Study shows pine bark improves circulation, swelling and visual acuity in early diabetic retinopathy 3Potential for non invasive brain tumor treatment 8852 1Potential for non invasive brain tumor treatment 8852 2Photos 3A FDA Clears Hologic R2 28TM 29 DigitalNow 28TM 29 HD Software Application 49044 1Photos 3A FDA Clears Hologic R2 28TM 29 DigitalNow 28TM 29 HD Software Application 49044 2Photos 3A FDA Clears Hologic R2 28TM 29 DigitalNow 28TM 29 HD Software Application 49044 3American Imaging Management Launches Program with Regence 49040 1American Imaging Management Launches Program with Regence 49040 2
...the University of Michigan Medical School have dis...arly-onset form of kidney disease and renal failur...d phospholipase C epsilon or PLCE1. , Identifying ... PLCE1 affects the development of podocytes ?speci...s ability to remove waste products from blood, whi...
... the Université de Montréal has concluded that peo...r a night of studying will strongly hurt their rec...he current issue of Neuropsychopharmacology was co...f Psychology at the Université de Montréal. Dr. Ca...ital du Sacré-Coeur de Montréal. , "We already kn...
...al studies of the interactions between oscillating...the toughest questions in ecology, including the n...ing to an article in the December 2006 issue of Bi...niversity of Michigan, shows how extensions of est... populations oscillate in synchrony because of int...
Other Biology News:Mutant gene causes severe kidney disease in infants 2Mutant gene causes severe kidney disease in infants 3Mutant gene causes severe kidney disease in infants 4Negative effects of caffeine are stronger on daytime sleep than on nocturnal sleep 2
4',6-diamidino-2-phenylindole, dihydrochloride (DAPI) *FluoroPure™ grade* from Molecular Probes (Invitrogen)
Proteins LabFax from Promega
Essential Data: Gel Electrophoresis from Promega
...ribes the basic equipment required, principles and...r and detection. Methods such as radiometric and b... included. Other topics covered are, the detection... chains and the study of DNA binding of immobilize...
Biology Products: